Reference: GILA/ID/SME-088/SHRIMPFEED
Board seat: Independent Director, Non-Executive
Primary board location: Vijayawada with plant and dealer/farm visits
Meeting model: Five boards, quarterly Audit/Risk and seasonal reviews
Mandate type: SME-to-Mainboard Governance Upgrade
Status: Confidential live-search specification; client identity released only after conflict clearance and NDA.
The anonymised enterprise
An SME-listed manufacturer of shrimp and fish feed selling through dealers and technical field teams in major aquaculture states.
Revenue is ₹800–1,200 crore. The company plans mainboard migration after expanding extrusion capacity and entering new coastal markets.
The board problem and strategic reason for appointment
The board needs to govern raw-material quality, dealer credit, farm outcomes, disease cycles, inventory and claims. Growth through channel push could create receivable and reputation risk.
The board is not buying a credential. It is appointing an independent decision-maker who can convert this problem into a governed sequence of choices, evidence and accountability. Success will be judged by the quality of decisions and control improvement, not by the number of recommendations made.
Board position, authority and interfaces
Audit/Risk member and board lead for product quality/channel governance.
The appointee will have direct, unfiltered access to the Company Secretary and to the relevant control-function leaders. Any advisory support requested by the board must remain management-executed: the director sets questions, tolerances and evidence standards, but does not become an executive or consultant.
First 12–18 month strategic charter
- Review formulation/raw-material substitutions, testing and batch traceability; build dealer inventory, credit and returns visibility by season; govern field claims, farm technical advice and disease-event escalation; challenge new-plant and market capex against feed conversion, utilisation and cash scenarios
- Rebuild governance for mainboard scale: committee depth, disclosure controls, investor communication, internal audit, board evaluation and management bandwidth must mature ahead of migration—not after it.
- Test whether reported growth is supported by cash, controls, customer quality and scalable systems; identify founder-dependent approvals and manual reconciliations that will fail under quarterly scrutiny.
Decision profile sought
Essential evidence
- Aquaculture, animal nutrition, food/feed manufacturing, audit or distribution leader; seasonal working-capital and product-quality judgement
Differentiators
- Disease-cycle response, dealer-credit reset or SME migration; export ingredient sourcing
GILA will assess public-market governance combined with respect for entrepreneurial operating speed, hands-on control building and the ability to challenge advisers selling migration as a transaction alone. Candidates should expect a case discussion based on an ambiguous board decision from this mandate, not a career-history interview alone.
Independence, suitability and downside diligence
The search will apply Section 149(6), Sections 164–165, Schedule IV and the applicable listing or sector rules to the entity’s legally verified status at the appointment date. Databank/proficiency status, listed-entity directorship and committee ceilings, pecuniary relationships, relatives’ interests, recent audit/advisory work and interlocking directorships will be checked. The appointment is subject to formal legal and secretarial confirmation; this posting is not a substitute for that determination.
Mandate-specific screens: Dealer, farm, hatchery, raw-material trader, lab or competitor interests; personal commodity positions; adviser conflicts.
Before accepting the seat, the candidate will receive under NDA the latest board composition, committee charters, material litigation/regulatory schedule, related-party map, last audited accounts, current D&O policy and the specific risk papers necessary to make an informed liability assessment.
Twelve-month outcomes
The board expects a migration-ready company with credible committees, clean disclosure ownership and systems able to support larger-market scrutiny. For this particular seat, the evidence will be:
- Batch and field-claim traceability works; channel credit/inventory stays visible; capex and disclosures reflect season/disease downside
Commitment, protection and economics
- Expected load: 22–28 days annually.
- Terms: Five-year term; committee fee; product, environmental and securities D&O cover.
- Protection: Appointment letter, deed of indemnity where legally available, appropriate D&O cover including discovery/run-off terms, access to independent advice under the board-approved protocol, and complete minuting of dissent.
- Equity: No stock options where the appointment is legally an independent-director seat subject to Section 149(9). Any private-company structure outside that perimeter will be expressly classified and separately advised; no equity is implied by this posting.
Search process
Conflict pre-clearance → GILA/SYMPHONY™ board-fit interview → mandate case → document-led diligence under NDA → references from board peers and control functions → NRC/owner interviews → statutory, regulatory and reputation checks → board recommendation. Candidate consent, disclosures and appointment approvals will follow the law and the entity’s constitutional documents.